SCIENTIFIC REPORTS

OPEN

Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients

Received: 19 July 2016
Accepted: 06 October 2016
Published: 13 December 2016

Tian-an Jiang¹, Zhuang Deng², Guo Tian³, Qi-yu Zhao¹ & Wei-lin Wang^{2,3}

This study aimed to compare the efficacy and safety of EUS-guided ethanol injection and ¹²⁵I seed brachytherapy for malignant left-sided liver tumors which were difficult for trans-abdominal intervention. The study protocol was registered at Clinicaltrials.gov (NCT02816944). Twenty-six patients were consecutively and prospectively hospitalized for EUS-guided interventional treatment of refractory malignant left-sided liver tumors between June 2014 and June 2016. Liver masses were detected using EUS in 25 of 26 (96.2%) patients. EUS-guided interventional treatment was completed uneventfully in 23 of 26 (88.5%) patients using anhydrous ethanol injection (n = 10) or iodine-125 seed implantation (n = 13). Six months later, complete response was achieved in 15 of 23 (65.2%) patients and partial response in 8 of 23 (34.8%) patients. Patients with tumor residual have second-look EUS-guided interventional treatment (n = 5), radiotherapy (n = 2) or surgical resection (n = 1). Complete response was achieved after repeated interventional treatment in 3 of 5 patients who underwent second EUS-guided intervention; 2 patients required additional surgical resection but one succeed. No significant complications occurred. Therefore EUS-guided ¹²⁵I seed brachytherapy is an effective and safe treatment modality for radical operation or promising palliative control of malignant left-sided liver tumors refractory to trans-abdominal intervention.

Malignant liver tumors, also known as liver cancer, chiefly consist of primary and metastatic hepatic and intrahepatic bile duct cancers, such as hepatocellular carcinoma, colorectal cancer liver metastasis, and cholangiocarcinoma¹. Liver cancer, which is usually asymptomatic at an early stage, may be incidentally detected on abdominal imaging scans, including those obtained by ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), or may manifest with signs and symptoms including abdominal pain, jaundice, hepatomegaly, abdominal mass, or hepatic dysfunction at a relatively late stage, at which point they are generally associated with a poor prognosis. Radical hepatectomy alone or followed by orthotopic liver transplantation remains the mainstay of treatment for resectable primary liver cancers², while radical resection of liver metastases is also beneficial for eligible colorectal cancer patients after neoadjuvant chemoradiation therapy³.

A majority of liver cancer cases are surgically refractory or unresectable possible because of underlying medical conditions, multiple or oversized liver diseases, or involvement of major vessels⁴. Palliative therapy, an alternative to definitive treatment, may help to improve patient survival and quality of life in these settings. Multiple palliative treatment regimens, including transarterial chemoembolization⁵, ablation using anhydrous ethanol injection⁶, high-intensity focused ultrasound⁷ or radiofrequency⁸, iodine-125 brachytherapy⁹, and photodynamic therapy¹⁰, have been used to control primary and secondary liver cancers. Among these documented palliative treatment modalities, ethanol injection and iodine-125 brachytherapy have shown promising therapeutic effects

¹Department of Ultrasound Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. ²Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. ³Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China. Correspondence and requests for materials should be addressed to W.-l.W. (email: wam@zju.edu.cn)

Figure 1. EUS-guided iodine-125 brachytherapy for postoperative liver metastasis of cholangiocarcinoma. (A) presence of a 1.3-cm, low-density liver mass located in the left lobe on CT scan (white arrows). US image failed to show the lesions due to the gas ahead; (B) identification of a 1.5 cm × 1.3 cm low-echodensity mass on EUS (white arrows); (C) EUS-guided implantation of iodine-125 particles (white arrows); (D) obvious downsizing of the liver disease on follow-up CT scan at 1 months (white arrows); and (E) disappearance of the liver disease on follow-up MRI scan taken after 12 months.

in liver cancer patients. These two treatment regimens are normally performed percutaneous access. In a few cases, thermal ablation performed in open surgery or under laparoscopy. While percutaneous intervention is generally thought to be minimally invasive, it may not be feasible for some patients with left hepatic lobe atrophy, lesion was located at the surgical margin of the left liver or in the caudate lobe, gastrointestinal flatulence and abdominal skin surgical scar. At this time, the conventional trans-abdominal ultrasound has difficulty to display lesions or even unable to discover it.

Endoscopic ultrasonography (EUS) is an advanced endoscopic technique primarily used for the characterization and biopsy of the gastrointestinal tract, particularly for preoperative staging of malignant diseases, including oesophageal, gastric, and pancreatic cancers¹¹. As left lobe of the liver is located in front of the lower esophagus, stomachus cardiacus and in proximity to the gastric lesser curvature, it is accessible on EUS, have better image quality and more adjacent to the focus. Therefore it is possible to interventionaly treat left-sided liver tumors through EUS, especially when other percutaneous intervention is not deemed feasible or safe. The present work aimed to compare the efficacy and safety of EUS-guided ethanol injection and ¹²⁵I seed brachytherapy for malignant liver tumors located in the left lobe that are refractory to conventional percutaneous intervention.

Figure 2. EUS-guided anhydrous ethanol ablation for postoperative liver recurrence of hepatocellular carcinoma. (A) presence of a 1.5 cm × 1.1 cm postoperative liver recurrence located on the resection margin as shown on T₂-weighted MRI scans (white arrows), but conventional US image failed to show the lesions; (B) EUS-guided ethanol injection; and (C) arterial phase (arrowhead) and (D) parenchymal phase (arrowhead): non-enhanced liver disease on follow-up contrast CT scan revealed complete resolution of disease at 12 months.

Item	¹²⁵ I	EI	Statistical value	P value
No. Cases	13	10		
Gender			NA [#]	0.197
male	6	8		
female	7	2		
Age	55.5 ± 7.6	56.2 ± 3.1	t = -0.176	0.862
Maximum diameter	2.8 ± 1.2	2.3 ± 0.6	t = -1.229	0.235
Histoty of disease			χ ² = 0.619	0.734
chronic hepatitis	3	3		
liver cirrhosis	4	4		
primary gastrointestinal malignancy	6	3		
Number of tumors				
single	12	6	NA [#]	0.343
multiple	2	3		
Recurrence	0	2	NA	NA

Table 1. Demographic characteristics of the patients. [#]means the result was calculated by Fisher's exact test; EI: ethanol injection; NA: not available.

Results

Demographic and clinical data. Overall, 26 patients were enrolled in this study, including 17 men and 9 women, aged 31–75 years. The basic characteristic of included patients was summarized in Table 1. The aetiologies of the hepatic tumors were chronic hepatitis (n = 6), liver cirrhosis (n = 11), and primary gastrointestinal malignancy (n = 9). Twenty-one patients had a single left-sided liver tumor, and 5 patients had more than one liver tumor with major disease located in the left lobe but multiple tumors in the right lobe. Liver tumors were occurred in left liver shadowed by gastrointestinal (GI) gas (n = 12; Fig. 1), resection margin (n = 7; Fig. 2),

Figure 3. EUS-guided anhydrous ethanol ablation for lesions in liver caudate lobe. MRI imaging in liver caudate lobe showed a lesion of low T1 signal intensity (A) (arrowhead) and significant enhancement in arterial phase (B) (arrowhead). (C) at liver caudate lobe EUS scan showed a well-defined hypoechoic 1.9*1.6 cm lesion (arrows). (D) It indicated that 22G biopsy needle with EUS guidance was inserted into the lesion along with the needle sheath (arrowhead), and (E) diffuse increase in echogenicity covering the whole mass after the percutaneously punctured injection of anhydrous alcohol. After 1 month follow-up, MR scan was seen high T1-weighted signal intensity (F) (arrowhead) and no obvious enhancement during arterial (G) (arrowhead) and substance phase (H) (arrowhead). After 15 months follow-up, it showed high T1-weighted signal intensity (I) (arrowhead) and contrast material-enhanced MR images showed completed ablation without enhanced lesions (J) (arrowhead).

caudate lobe (n = 3; Fig. 3), significantly atrophic left lobe (n = 2), and remarkable abdominal skin scar (n = 2). All tumors were not detectable or poorly visualised on percutaneous ultrasound scan because of the above reason. In addition, a systematic review by searching from PubMed up to August 2016 was performed. The summary of 11 studies of ethanol ablation and ^{125}I brachytherapy of the hepatocellular carcinoma was presented in Table 2^{12–17} and Table 3^{9,18–21}.

Author	Year	Country	Characteristics of patients	Treatment method	Patients(No. of tumors)	Tumor size	Male/female	Mean age(range)	Follow-up interval(months)	Prognosis	Complication
Nakaji S <i>et al.</i>	2015	Japan	Patient with HCC in the left hepatic lobe	Eus-guided EI	1	45	0/1	79	1	CR	No
Nakaji S <i>et al.</i>	2012	Japan	Patient with HCC	Eus-guided EI	1(2)	13 and 17	1	82	0.5	CR	NA
Azab M <i>et al.</i>	2011	Egypt	Patient with HCC	US-guided PEI	32	NA	NA	46–77	18	24 CR;8 PR	25 transient pain;2 portal vein thrombosis;3 fever;3 mild ascites
Giorgio A <i>et al.</i>	2011	Italy	Patient with HCC	US-guided PEI	142	23.4 ± 4.5 (11–30)	105/37	70 ± 2 (68–74)	22	3- and 5-year survival rates:74% and 68%;3- and 5-year local recurrence rates were 9.4% and 12.8%	Major complications was 1.9%
Brunello F <i>et al.</i>	2008	Italy	Patient with HCC	US-guided PEI	69 (88)	22.5 ± 5.4	49/20	70.3 ± 8.1	25.3	1-year OS rate 83.3%	1 haemoperitoneum;1 death
Shiina S <i>et al.</i>	2005	Japan	Patient with HCC	US-guided PEI	114 (192)	45 ≤ 2 cm; 73 > 2 cm	87/27	41 ≤ 65; 73 > 65	34.8(1.2–50.4)	a) Solitary tumor: 1-, 3- and 4-year survival rates:95%, 85%, 73%, and 64%; b) multiple tumors:1-, 3- and 4-year survival rates:93%, 78%, 60%, and 48%	1 liver abscess;2 neoplastic seeding

Table 2. Summary of ethanol injection for treatment of hepatocellular carcinoma. HCC: hepatic cellular cancer; US: ultrasound; EI: ethanol injection; PEI: percutaneous ethanol injection; NA: not available; CR: complete response; PR: partial response; OS: overall survival.

EUS data. Out of the 26 patients, left-sided liver tumors were detectable in all cases on EUS with the exception of one (1/26, 3.8%) case in which the tumor was located in an atrophic left lobe. Of these 25 cases, 23 were successfully and uneventfully treated using interventional EUS (anhydrous ethanol, $n = 10$; iodine-125 implant, $n = 13$) as scheduled. Interventional treatment failed in two patients due to an overly large puncture angulation. Operative time was 10–70 minutes, and no blood loss. No clinically significant procedure-related morbidities occurred.

Tumor response and mid-term follow-up data. All patients were followed up for 1–2.5 years as scheduled. At 12 months after treatment, 12 of 13 (92.3%) patients achieved complete tumor response in iodine-125 particle implantation (Fig. 1) while 3 of 10 (30%) in anhydrous ethanol ablation (Fig. 3 and Table 4). Residual tumor was detected in 8 patients after anhydrous ethanol ablation ($n = 2$) or iodine-125 particle implantation ($n = 6$); these patients were further treated with second-look EUS-guided interventional treatment ($n = 5$) and radiotherapy ($n = 2$) and surgical resection ($n = 1$). Complete response was achieved after again EUS-guided treatment in 3 of 5 patients, whereas the remaining 2 patients required surgical resection but only one succeeded. Recurrence was observed in 2 patients at 1 year after anhydrous ethanol ablation. No clinically significant late-onset complications occurred.

Discussion

Interventional EUS, namely, EUS-guided interventional treatment, has been reported for drainage of pancreatic²² or bile duct (pseudo) cysts²³ or even complex choledochoduodenostomy²⁴. This newly emerging interventional treatment incorporating ethanol or chemotherapy injection, brachytherapy, and/or photodynamic therapy has also been piloted in preclinical studies and a small series of clinical studies for the treatment of malignant pancreatic, lower common bile duct, and periampullary diseases²⁵. In contrast, EUS is used relatively less frequently for the treatment of hepatic tumors. Awad *et al.*²⁶ reported that EUS could detect small-sized primary and secondary liver cancers previously undetectable on CT scans, and simultaneous fine-needle biopsy aided in the diagnosis of deep-seated liver tumors for preoperative staging. Singh *et al.*²⁷ also reported, in a small series of prospective patients, that EUS exhibited a higher specificity and positive predictive value than CT and percutaneous ultrasound scanning for metastatic liver tumors located in hepatic segments II and III. Furthermore, interventional EUS has been attempted for transgastric drainage of liver abscess²⁸ and infectious biloma after radiofrequency-ablated hepatocellular carcinoma²⁹. To the best of our knowledge, the present work is the first prospective study comparing the therapeutic role of EUS-guided ethanol injection and ¹²⁵I seed brachytherapy in the treatment of left-sided liver malignancies.

Percutaneous ultrasonography-guided interventional treatment normally requires an acoustic window to clearly display the liver tumor and allow subsequent ethanol injection, high-intensity focused ultrasound³⁰, or other ablation therapy. However, in some patients, such as those enrolled in the current study, hepatic tumors cannot be detected or clearly visualised on percutaneous ultrasound scanning because of distorted liver anatomy from a previous operation, a deep-seated location such as the caudate lobe, at the edge of liver, at the surgical margin that usually affected by gastrointestinal gas or a pre-existing abdominal scar. For left-sided liver tumors, especially when located in proximity to the lesser curvature of the stomach, transgastric EUS can exclude the interference of intestinal gas and provide safe liver access for ethanol injection and iodine-125 implantation. Our results showed that EUS-guided iodine-125 brachytherapy has a better prognosis and less recurrence for left-sided liver tumors with a good safety profile comparing to ethanol ablation. Moreover, iodine-125

Author	Year	Country	Characteristics of patients	Treatment method	Patients(No. of tumors)	Tumor size	Number of seeds	Male/female	Mean age(range)	Follow-up interval(months)	Prognosis	Complication
Zhang W <i>et al.</i>	2015	China	1 patient with Bismuth type IV Klatskin tumor	DSA	1	NA	12	1	75	3	Improved	NA
Chen K <i>et al.</i>	2013	China	Patients with hepatocellular carcinoma after complete hepatectomy	¹²⁵ I brachytherapy	34(38)	6.24 ± 2.55	25 (18–34)	25/9	18–70	47.6 (7.7–106.4)	Time to recurrence:60 months;1-, 3- and 5-year recurrence-free rates:94.12%, 76.42%, and 73.65%;1-, 3- and 5-year OS rates:94.12%, 73.53%, and 55.88%.	1 nausea;1 sinus tachycardia;1 premature atrial contraction
Luo J <i>et al.</i>	2011	China	Patients with HCC complicated by tumor thrombus in main portal vein	US-guided ¹²⁵ I seed strand and stent with chemoembolization	32	87.6 ± 28.2 (53–175)	17	28/4	53.2 ± 8.8 (30–76)	7.3 ± 5.1	Technical success rate was 100%; the 3-month, 6-month, and 12-month cumulative survival rates were 96.4%, 67.4%, and 39.3%, and the cumulative stent patency rates were 96.7%, 83.4%, and 83.4%	Fever, vomiting or upper abdominal pain
Zhang FJ <i>et al.</i>	2008	China	Patients with HCC of PVTT	US-guided ¹²⁵ I brachytherapy	19	11 ≥ 5 cm; 8 < 5 cm	18–30	13/6	57 (37–68)	3–22	12 CR;4 PR; 3 stable	Mild pain;1 hemothorax
Nag S <i>et al.</i>	2006	America	Patients with unresectable or residual disease after surgical resection	¹²⁵ I brachytherapy	64(309)	NA	40 (10–134)	33/31	57.4 (30–81)	158.4 (20–175)	Median time to recurrence:9 months (6–12 months);1-, 3- and 5-year intrahepatic local control rates were 44%, 22%, and 22%;1-, 3- and 5-year OS rates were 73%, 23%, and 5%	2 died;1 small-bowel obstruction;1 small-bowel perforation;1 liver abscess;1 wound abscess.

Table 3. Summary of ¹²⁵I brachytherapy for treatment of hepatocellular carcinoma. HCC: hepatic cellular cancer; PVTT: portal vein tumor thrombosis; DSA:digital subtraction angiography; US: ultrasound; NA: not available; CR: complete response; PR: partial response; OS: overall survival.

implantation is recommended for the treatment of larger tumors because of a higher risk of residual or recurrent tumor. In previous study, it was reported that the 1-, 3- and 5-year recurrence-free rates of the ¹²⁵I brachytherapy after resection of HCC were 94.12%, 76.42%, and 73.65%, and their overall survival rates were 94.12%, 73.53%, and 55.88%, respectively⁹, which was also similar to another study²¹. This may result from that a high-dose short radiation emitted by ¹²⁵I could be continuous within the target tissues for a long half-life of 59.4 days, which would trigger tumor cell apoptosis and drop proliferation of tumor cells by gathering cells in the radiosensitive cell cycle phase (G2/M)^{20,31}. The radiation declined sharply with the distance from the seeds and had limited injury to surrounding normal tissues. Meanwhile, ¹²⁵I implantation also could excite the anti-tumor immune response in HCC patients by adding CD3+ and CD4+ immunocytes and facilitating Th2/Th1 deviation³². Thus these findings indicated that EUS-guided ¹²⁵I brachytherapy could be a safe and feasible way to effectively target tumor cells and minimize injury to healthy tissues.

There are some limitations regarding EUS-guided interventional treatment of liver cancer. First, interventional EUS requires a more delicate ultrasound system and greater operator expertise; therefore, this interventional technique is less feasible in general ultrasonographic practice. Second, transgastric EUS can only access a relatively small portion of the left lobe; an overly large puncture angulation failed the pre-planned interventional therapy in 2 of our patients. Third, implantation of radioactive particles is relatively complex through a EUS puncture needle compared to the percutaneous approach.

In conclusion, EUS-guided iodine-125 brachytherapy is an effective alternative to ethanol injection for radical operation or promising palliative control of refractory malignant left-sided liver tumors. This technique is minimally invasive and associated with a good safety profile, and residual tumor can be treated by repeated sessions of interventional EUS. The long-term efficacy and safety of interventional EUS have yet to be investigated in large-scale, comparative studies, especially studies evaluating patients' survival and quality of life.

Patients and Methods

Patient selection. Between June 2014 and June 2016, 26 patients with primary or metastatic left-sided liver tumors diagnosed on abdominal ultrasound, CT, and/or MRI scans, who were ineligible for surgical treatment due to unresectable disease or high risk of surgical morbidity, were consecutively and prospectively referred to our ultrasound centre for palliative treatment. The included patients were randomly divided into two groups: 10 in the anhydrous ethanol group and 13 in the iodine-125 implantation group. Inclusion criteria were as follows: American Society of Anaesthesiologists physical status class I and II; relatively well confined, single hepatic tumor or extensive hepatic tumor (in the scenario of multiple foci) located in Couinaud segments I–III refractory to

Item	¹²⁵ I	EI	Statistical value	P value
CR	12	3	NA [#]	0.006
PR	1	7		

Table 4. Result of the patients in anhydrous ethanol injection group and iodine-125 seed implantation group. [#]means the result was calculated by Fisher's exact test; EI: ethanol injection; CR: complete response; PR: partial response; NA: not available.

percutaneous access; liver tumor that could not be visualised or not clearly visualised on percutaneous ultrasound; and generally normal or compensated liver function (Child-Pugh classes A and B). Exclusion criteria were as follows: a known history of or suspected upper gastrointestinal stenosis or stricture; complicating oesophago-gastric varices or bleeding; pre-existing serious cardiopulmonary or hepatorenal functional impairment or coagulopathy; extensive intra- or extrahepatic metastases; or refusal to participate in the study. All patients provided informed consent in writing prior to enrolment.

Ethical issues. This was designed as a randomized, open-label, control study. The clinical trial was registered in Clinicaltrials.gov ID: NCT02816944 on June 23th 2016. All patients and relatives were informed about the purpose and procedures of this study and gave written informed consent. Eligible patients were randomly allocated into the ¹²⁵I brachytherapy group and the control group of ethanol ablation. The study was approved by the Institutional Review Board at the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou and all studies were conducted in accordance with relevant guidelines and regulations.

EUS and interventional treatment procedures. All patients underwent routine hematologic, clinical biochemical, coagulative function, virologic, and oncologic assays prior to interventional EUS. All interventional procedures were performed by an assigned interventional treatment team led by a board-certified interventional physician, including resident interventional physicians, radiologists, and research nurses.

Left-sided liver EUS was performed as previously described²⁸. Briefly, the patient was placed in the left recumbent position and sedated using intravenous propofol. After excluding the presence of oesophagogastric varices using conventional endoscopy, a Pentax endoscopic ultrasound system (Pentax Medical, Tokyo, Japan) incorporating a Hitachi colour Doppler ultrasound scanner (Hitachi Medical, Tokyo, Japan) was used for EUS of the left-sided liver. An endoscopic ultrasound injection needle (Cook Medical, Bloomington, IN, USA) was used for injection of anhydrous ethanol (22G) for well-encapsulated primary hepatocellular carcinoma or implantation of iodine-125 particles (19G; Cook Medical, Bloomington, IN, USA) for hepatocellular carcinoma, cholangiocellular carcinoma or metastatic liver cancer.

Postoperative care, follow-up procedure, and main outcome measures. Patients were closely followed after EUS and treated with antimicrobial, haemostatic, and hepatoprotective agents as indicated. All patients were followed up at the outpatient clinic using abdominal ultrasound, CT, and/or MRI at 1, 3, 6, and 12 months postoperatively. The main outcome measures were frequency of detection by EUS, tumor response as defined by the *Response Evaluation Criteria in Solid Tumors*³⁰ at 6 months, and interventional EUS-associated morbidities. In this study, all statistical analysis was performed using χ^2 , Fisher exact test and Student t test by spss 13.0 software.

References

- Fowler, K. J., Saad, N. E. & Linehan, D. Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. *Surgical oncology clinics of North America* **24**, 19–40, doi: 10.1016/j.soc.2014.09.002 (2015).
- Pichlmayr, R., Weimann, A., Tusch, G. & Schlitt, H. J. Indications and Role of Liver Transplantation for Malignant Tumors. *The oncologist* **2**, 164–170 (1997).
- Khan, K., Wale, A., Brown, G. & Chau, I. Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? *World journal of gastroenterology* **20**, 12391–12406, doi: 10.3748/wjg.v20.i35.12391 (2014).
- Wang, H. M. *et al.* Analysis of facial bone wall dimensions and sagittal root position in the maxillary esthetic zone: a retrospective study using cone beam computed tomography. *The International journal of oral & maxillofacial implants* **29**, 1123–1129, doi: 10.11607/jomi.3348 (2014).
- Takayasu, K. *et al.* Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* **131**, 461–469, doi: 10.1053/j.gastro.2006.05.021 (2006).
- Horiguchi, Y. *et al.* Treatment of choice for unresectable small liver cancer: percutaneous ethanol injection therapy or transarterial chemoembolization therapy. *Cancer chemotherapy and pharmacology* **33** Suppl, S111–S114 (1994).
- Hoang, N. H., Murad, H. Y., Ratnayaka, S. H., Chen, C. & Khismatullin, D. B. Synergistic ablation of liver tissue and liver cancer cells with high-intensity focused ultrasound and ethanol. *Ultrasound in medicine & biology* **40**, 1869–1881, doi: 10.1016/j.ultrasmedbio.2014.02.026 (2014).
- Weis, S., Franke, A., Mossner, J., Jakobsen, J. C. & Schoppmeyer, K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. *The Cochrane database of systematic reviews*, CD003046, doi: 10.1002/14651858.CD003046.pub3 (2013).
- Chen, K. *et al.* Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. *PloS one* **8**, e57397, doi: 10.1371/journal.pone.0057397 (2013).
- Wang, J. D. *et al.* Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer. *Lasers in medical science* **28**, 1541–1548, doi: 10.1007/s10103-012-1248-3 (2013).
- Holt, B. & Varadarajulu, S. Endoscopic ultrasound-guided fine needle aspiration or fine needle biopsy: the beauty is in the eye of the beholder. *Endoscopy* **46**, 1046–1048 (2014).

12. Nakaji, S., Hirata, N., Kobayashi, M., Shiratori, T. & Sanagawa, M. Endoscopic ultrasonography-guided ethanol injection as a treatment for ruptured hepatocellular carcinoma in the left hepatic lobe. *Endoscopy* **47** Suppl 1, E558–E560, doi: 10.1055/s-0034-1393394 (2015).
13. Nakaji, S. *et al.* Endoscopic ultrasound (EUS)-guided ethanol injection for hepatocellular carcinoma difficult to treat with percutaneous local treatment. *Endoscopy* **44** Suppl 2 UCTN, E380, doi: 10.1055/s-0032-1309918 (2012).
14. Azab, M. *et al.* Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. *Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology* **12**, 113–118, doi: 10.1016/j.ajg.2011.07.005 (2011).
15. Giorgio, A. *et al.* Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. *Anticancer research* **31**, 2291–2295 (2011).
16. Brunello, F. *et al.* Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. *Scandinavian journal of gastroenterology* **43**, 727–735, doi: 10.1080/00365520701885481 (2008).
17. Shiina, S. *et al.* A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology* **129**, 122–130 (2005).
18. Zhang, W. *et al.* Placement of (1)(2)(5)I seed strands and stents for a type IV Klatskin tumor. *World journal of gastroenterology* **21**, 373–376, doi: 10.3748/wjg.v21.i1.373 (2015).
19. Luo, J., Yan, Z., Liu, Q., Qu, X. & Wang, J. Endovascular placement of iodine-125 seed strand and stent combined with chemembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. *Journal of vascular and interventional radiology: JVIR* **22**, 479–489, doi: 10.1016/j.jvir.2010.11.029 (2011).
20. Zhang, F. J. *et al.* CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. *Chinese medical journal* **121**, 2410–2414 (2008).
21. Nag, S., DeHaan, M., Scruggs, G., Mayr, N. & Martin, E. W. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. *International journal of radiation oncology, biology, physics* **64**, 736–744, doi: 10.1016/j.ijrobp.2005.08.029 (2006).
22. Bang, J. Y. & Varadarajulu, S. Endoscopic ultrasound-guided management of pancreatic pseudocysts and walled-off necrosis. *Clinical endoscopy* **47**, 429–431, doi: 10.5946/ce.2014.47.5.429 (2014).
23. Puspok, A. *et al.* Endoscopic ultrasound guided therapy of benign and malignant biliary obstruction: a case series. *The American journal of gastroenterology* **100**, 1743–1747, doi: 10.1111/j.1572-0241.2005.41806.x (2005).
24. Artifon, E. L. *et al.* Endoscopic ultrasound-guided choledochoduodenostomy and duodenal stenting in patients with unresectable periampullary cancer: one-step procedure by using linear echoendoscope. *Scandinavian journal of gastroenterology* **48**, 374–379, doi: 10.3109/00365521.2012.763176 (2013).
25. Zhang, W. Y., Li, Z. S. & Jin, Z. D. Endoscopic ultrasound-guided ethanol ablation therapy for tumors. *World journal of gastroenterology* **19**, 3397–3403, doi: 10.3748/wjg.v19.i22.3397 (2013).
26. Awad, S. S. *et al.* Preoperative evaluation of hepatic lesions for the staging of hepatocellular and metastatic liver carcinoma using endoscopic ultrasonography. *American journal of surgery* **184**, 601–604; discussion 604–605 (2002).
27. Singh, P. *et al.* Endoscopic ultrasound versus CT scan for detection of the metastases to the liver: results of a prospective comparative study. *Journal of clinical gastroenterology* **43**, 367–373, doi: 10.1097/MCG.0b013e318167b8cc (2009).
28. Tonozuka, R. *et al.* EUS-guided drainage of hepatic abscess and infected biloma using short and long metal stents (with videos). *Gastrointestinal endoscopy* **81**, 1463–1469, doi: 10.1016/j.gie.2015.01.023 (2015).
29. Eso, Y., Marusawa, H., Tsumura, T., Okabe, Y. & Osaki, Y. Endoscopic ultrasonography-guided transgastric drainage of infectious biloma following radiofrequency ablation for hepatocellular carcinoma. *Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society* **24**, 390, doi: 10.1111/j.1443-1661.2012.01305.x (2012).
30. Silva, M. F. *et al.* m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma. *Annals of hepatology* **13**, 796–802 (2014).
31. Zhuang, H. Q., Wang, J. J., Liao, A. Y., Wang, J. D. & Zhao, Y. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. *Journal of experimental & clinical cancer research: CR* **28**, 12, doi: 10.1186/1756-9966-28-12 (2009).
32. Xiang, G. A., Chen, K. Y., Wang, H. N. & Xiao, J. F. [Immunological influence of iodine-125 implantation in patients with hepatocellular carcinoma resection]. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University* **30**, 292–294 (2010).

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81572307), the Science and Technology Project of Zhejiang Province (2014C13G2010059). The funders had a role in preparation of the manuscript and publication.

Author Contributions

W.-I.W. and T.-a.J. conceived the project, designed the research and wrote the article. T.-a.J., Z.D., G.T. and Q.-y.Z. were responsible for the EUS treatment and clinical data collection. W.-I.W., T.-a.J. and Z.D. were responsible for statistical analysis. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Jiang, T.-a *et al.* Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients. *Sci. Rep.* **6**, 36098; doi: 10.1038/srep36098 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016